Physician profile
Sofia Palacio Cardenas
NPI 1063776086
$4,567.64
in general payments reported to CMS, 2019-2025
35 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $32.01 · 2021: $1,313 · 2022: $375 · 2023: $1,822 · 2024: $714 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.84 |
| Consulting Fee | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,287.32 | 2021-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $337.17 | 2023-2025 | Lynparza |
| Janssen Biotech, INC. | $263.04 | 2021-2024 | Tecvayli, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $219.30 | 2019-2024 | Krazati, Opdivo |
| Stemline Therapeutics INC. | $214.27 | 2023-2024 | Orserdu |
| Puma Biotechnology, INC. | $168.23 | 2021-2024 | |
| Gilead Sciences, INC. | $150.45 | 2021-2024 | Trodelvy |
| Janssen Pharmaceuticals, INC | $123.26 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $62.66 | 2019-2024 | |
| Genentech, INC. | $53.60 | 2022 | |
| Genzyme Corporation | $50.81 | 2021-2024 | |
| Celgene Corporation | $48.41 | 2019 | |
| Merck Sharp & Dohme LLC | $42.74 | 2024 | Keytruda |
| Eisai INC. | $41.53 | 2023-2024 | |
| Seagen INC. | $40.02 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $39.72 | 2022-2024 | Brukinsa |
| Abbvie INC. | $38.84 | 2019-2024 | |
| Emd Serono, INC. | $34.55 | 2021-2022 | |
| Exelixis INC. | $32.27 | 2019 | |
| Acrotech Biopharma INC. | $29.85 | 2021-2024 | Beleodaq |
| Regeneron Healthcare Solutions, INC. | $29.74 | 2019 | |
| Genentech USA, INC. | $28.74 | 2024 | Rozlytrek, Polivy, Lunsumio |
| Aveo Pharmaceuticals, INC. | $27.83 | 2022 | |
| Amgen INC. | $24.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.68 | 2024 | Alunbrig |
| Taiho Oncology, INC. | $16.83 | 2020 | |
| Incyte Corporation | $16.45 | 2021 | |
| Aurobindo Pharma USA, INC. | $16.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.88 | 2022 | |
| Pfizer INC. | $15.74 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.54 | 2021 | |
| Astellas Pharma US INC | $15.47 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $15.18 | 2020 | |
| Pharmacosmos Therapeutics INC. | $15.10 | 2024 | Monoferric |
| Axonics, INC. | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Palacio Cardenas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.